Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Archibald Skemp (NPI 1386648236)

Field	Value
Entity Type	Individual
Organization	Archibald Skemp
Address	7600 France Ave S Ste 5100
City	Edina
State	MN
ZIP	55435
Taxonomy	Rheumatology Physician
NPI Enumerated	June 9, 2005

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

Practice profile and service mix: ARCHIBALD SKEMP (Rheumatology Physician) shows a billing mix dominated by infused biologic drugs — leading codes include J9312, J0129, J1745 and additional biologic agents such as J3262 and J1602 — indicating the provider operates with a significant in‑office or supervised infusion service line rather than primarily delivering only routine clinic visits. Supportive infusion/chemotherapy administration codes (for example 96413 and the add‑on 96415) also appear on the record, consistent with repeated IV administration workflows and ancillary infusion services.

Revenue concentration: This provider’s top three Medicare revenue codes (J9312 at $280.4K, J0129 at $256.6K, and J1745 at $214.9K) together account for 66.3% of the provider’s total Medicare revenue, showing heavy dependence on a narrow set of high‑cost biologic drug administrations for the majority of Medicare receipts. That concentration points to a business model where a few biologic agents drive most of the practice’s payer revenue.

Payer mix and scale: The provider’s lifetime Medicare revenue is $1.1M while Medicaid shows none (no Medicaid billing on file), so the practice is effectively single‑payer with Medicare as the dominant and only public payer captured in the data. This limits visibility into non‑Medicare payer behavior and suggests any Medicaid network strategies or exposure are minimal or absent in the claims on file.

Competitive standing on top biologics: For rituximab (J9312, $280.4K) the provider ranks #86 of 317 nationally (73th percentile) which is described as typical, unremarkable volume relative to peers; for abatacept (J0129, $256.6K) the rank is #650 of 1221 (47th percentile) and likewise typical; conversely infliximab (J1745, $214.9K) ranks #141 of 1352 (90th percentile), indicating a comparatively strong national presence for that specific agent versus peers. Taken together, these ranks suggest the provider is a specialized but modestly positioned infusion participant—top performer for some agents but otherwise within typical volume ranges.

Notable statistical outliers in retention/infusion time: The add‑on infusion code 96415 is labeled as notably above typical national volume (rank #219 of 4959, 96th percentile), which may reflect frequent extended infusions or repeated hourly add‑ons in sessions. That elevated standing for 96415, alongside large biologic drug volumes, implies operational capacity for longer or repeated infusion sessions compared with most peers.

Role of office visits and labs: Evaluation & management visits and routine lab testing together represent a small portion of reported Medicare revenue (for example 99214 at $32.7K, 2.9% of Medicare revenue) while a range of laboratory codes (85025, 86235, 82565, 82040, etc.) appear at low revenue levels. This pattern is consistent with a care model organized around drug administration where office encounter and lab billing supplement, rather than drive, the revenue stream.

Tenure and market presence: The provider’s NPI was enumerated on 2005-06-09 (~21 years ago), indicating long-standing enrollment in Medicare which supports an established practice and likely a stable referral or infusion workflow developed over many years. Longevity combined with concentration in biologics suggests entrenched niche operations rather than a recent entrant shifting into infusion services.

Risk and operational implications for payers: Given the heavy reliance on a small set of high‑cost biologics (top three codes = 66.3% of Medicare revenue) and absence of Medicaid billing, payers evaluating network value or utilization management should focus on drug utilization patterns (J9312, J0129, J1745) and infusion staffing/capacity practices (notably high 96415 volumes) to assess cost drivers and opportunities for pathway management or site‑of‑care considerations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9312	Injection, rituximab, 10 mg	4,450	$60	$280.4K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	7,780	$30	$256.6K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	8,270	$30	$214.9K
J3262	Injection, tocilizumab, 1 mg	26,440	$10	$132.2K
J1602	Injection, golimumab, 1 mg, for intravenous use	11,450	$10	$126K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	450	$110	$47.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	360	$90	$32.7K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	90	$140	$12K
96415	In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the…	330	$20	$7.5K
36415	In this procedure, the provider inserts a needle into a vein to collect a blood sample.	380	$10	$3K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Archibald Skemp — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	7	20	5,330	$30	$242.9K
J9312	2	10	4,030	$60	$231.9K
J3262	9	20	26,440	$1	$147.6K
J1602	7	20	7,050	$10	$112K
J1745	5	60	1,540	$30	$76.7K
96413	6	230	70	$100	$11.5K
86235	5	20	100	$20	$11.2K
99214	368	10,100	70	$80	$8.1K
99215	621	4,060	30	$120	$5.9K
99205	827	1,350	20	$150	$4.1K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with Archibald Skemp, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Susan Leonard	MN	Rheumatology Physician	$1M	$0
Grace Skemp-dymond	MN	Rheumatology Physician	$971.4K	$0
Sara Baig	MN	Rheumatology Physician	$736.2K	$0
Hammad Bajwa	MN	Rheumatology Physician	$694.8K	$0
Kurt Zimmerman	MN	Rheumatology Physician	$672.4K	$0
Maren Hilton	MN	Rheumatology Physician	$648.8K	$0
Anne Wolff	MN	Rheumatology Physician	$541.6K	$0
Jeffrey Wilson	MN	Rheumatology Physician	$402.5K	$0
Angela Dahle	MN	Rheumatology Physician	$346.1K	$0
Nicholas Lebedoff	MN	Rheumatology Physician	$322.6K	$0

Nearby Providers

Other providers in the same ZIP code as Archibald Skemp, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Emergency Physicians Professional Association	MN	Emergency Medicine Physician	$0	$72.7M
Vitreoretinal Surgery PLLC	MN	Ophthalmology Physician	$0	$27.8M
Fairview Health Services	MN	General Acute Care Hospital	$0	$17.2M
Professional Resource Network - Prn - Corporation	MN	Home Health Agency	$0	$12.4M
Virtual Radiologic Professionals, LLC	MN	Diagnostic Radiology Physician	$0	$11.3M
Mental Health Systems PC	MN	Psychologist	$0	$11M
Premier Obgyn Of Minnesota PLLC	MN	Obstetrics & Gynecology Physician	$0	$7M
Noran Neurological Clinic P.A.	MN	Specialist	$0	$6M
Nura Surgical Center LLC	MN	Ambulatory Surgical Clinic/Center	$5.3M	$581.7K
Southdale Pediatric Associates, Ltd	MN	Multi-Specialty Clinic/Center	$0	$5.3M

Archibald Skemp — Billing Profile & Reimbursement Data

Sign up for Archibald Skemp — Billing Profile & Reimbursement Data policy alerts

Archibald Skemp — Billing Profile & Reimbursement Data

Sign up for Archibald Skemp — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References